Edwards SAPIEN 3 Transcatheter Heart Valve (9600TFX), Edwards SAPIEN 3 Ultra Transcatheter Heart Valve (9750TFX)
Edwards Lifesciences, LLC · Decision date Oct 28, 2026
What did the FDA decide?
This 30-Day Notice for supplement S210 to PMA P140031 records a process change: implementing an alternative supplier of a chemical manufacturing aid. The affected devices are the Edwards SAPIEN 3 Transcatheter Heart Valve (9600TFX) and the Edwards SAPIEN 3 Ultra Transcatheter Heart Valve (9750TFX), both percutaneously delivered aortic valve prostheses under product code NPT.
The notice does not state which chemical manufacturing aid, which manufacturing step, or which supplier is involved. The FDA decision field reads "OK30," but the source does not define that code. This supplement is not a new approval of the valve systems and does not establish safety or effectiveness; it only reports the supplier change.
FDA approval order statement
implementing an alternative supplier of a chemical manufacturing aid
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Cardiovascular
- Decision date
- Oct 28, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P140031/S210
- Regulatory pathway
- PMA supplement
- Applicant
- Edwards Lifesciences, LLC
- Product code
- NPT
- Decision code
- OK30
- Decision date
- Oct 28, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Aortic valve, prosthesis, percutaneously delivered.
- Applicant
- Edwards Lifesciences, LLC
- Product code
- NPT
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P140031. Subsequent supplements may change the device or its indications.
FDA decision timeline
P140031 · Original PMA
SAPIEN 3 TRANSCATHETER HEART VALVE AND ACCESSORIES
P140031/S209 · Related supplement
Edwards Crimper (9600LDS23, 9600LDS26, 9600LDS29, 9750CM20, 9750CM23, 9750CM26, 9750CM29)
P140031/S210 received
Application receipt date recorded by FDA.
P140031/S202 · Related supplement
Edwards SAPIEN 3 Ultra RESILIA Transcatheter Heart Valve
P140031/S210 · FDA decision
30-Day Notice
Timeline entries are records held by MedtechLedger for P140031. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P140031
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Edwards Lifesciences, LLC | PMA approval | Jun 17, 2015 | FDA | |
| Edwards Lifesciences, LLC | PMA supplement | Sep 23, 2026 | FDA | |
| Edwards Lifesciences, LLC | PMA supplement | Oct 22, 2026 | FDA |
Explore the linked device profile
Other records with product code NPT
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Medtronic, Inc. | PMA supplement | Nov 7, 2026 | FDA | |
| ABBOTT MEDICAL | PMA supplement | Oct 29, 2026 | FDA | |
Trilogy Transcatheter Heart Valve SystemP250024/S005 | JenaValve Technology, Inc. | PMA supplement | Oct 13, 2026 | FDA |
Trilogy Transcatheter Heart Valve SystemP250024/S006 | JenaValve Technology, Inc. | PMA supplement | Oct 7, 2026 | FDA |
| JenaValve Technology, Inc. | PMA approval | Mar 17, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Edwards Lifesciences, LLC
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- One Edwards Way, Irvine, CA, 92614
Sources and methodology
- Original FDA record: P140031/S210
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records
